Verrica Pharmaceuticals
VRCA
81 hedge funds and large institutions have $21M invested in Verrica Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 22 increasing their positions, 18 reducing their positions, and 16 closing their positions.
25% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 16
22% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 18
3% more funds holding
Funds holding: 79 → 81 (+2)
0.17% less ownership
Funds ownership: 3.49% → 3.32% (-0.17%)
3% less capital invested
Capital invested by funds: $21.6M → $21M (-$568K)
50% less call options, than puts
Call options by funds: $2K | Put options by funds: $4K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$9.81M |
| 2 |
CP
Caligan Partners
New York
|
+$8.17M |
| 3 |
BFM
Boothbay Fund Management
New York
|
+$2.84M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$652K |
| 5 |
HCM
Heights Capital Management
San Francisco,
California
|
+$386K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$4.23M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$681K |
| 3 |
PBM
Propel Bio Management
Los Angeles,
California
|
-$500K |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$315K |
| 5 |
SAM
Simplify Asset Management
Las Vegas,
Nevada
|
-$290K |
VRCA Hedge Fund Activity: Q4 2024 in Review
81 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Verrica Pharmaceuticals (VRCA) for Q4 2024, worth a combined $21M — down 2.6% from $21.6M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new VRCA positions and 16 closed out — a net gain of 4 holders — while 22 added to existing stakes and 18 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $9.81M. The largest seller was Perceptive Advisors, cutting an estimated $4.23M.
- 81 institutional investors held Verrica Pharmaceuticals (VRCA) as of Q4 2024, up from 79 in Q3 2024.
- Funds reported $21M of Verrica Pharmaceuticals stock for Q4 2024, down 2.6% quarter-over-quarter.
- 20 funds opened new Verrica Pharmaceuticals positions in Q4 2024 and 16 closed out, a net change of +4 holders.
- The largest Verrica Pharmaceuticals buyer in Q4 2024 was Armistice Capital, an estimated $9.81M added.
- The largest Verrica Pharmaceuticals seller in Q4 2024 was Perceptive Advisors, an estimated $4.23M sold.
Based on aggregated 13F filings for Q4 2024.